PANCREATIC DUCTAL ADENOCARCINOMA

This study tested whether adding two immunotherapy drugs (pembrolizumab and defactinib) to standard chemotherapy could help the immune system fight pancreatic cancer before and after surgery. Twenty-eight adults with early-stage, removable pancreatic cancer participated. The goal…

This early-phase trial tested a new immunotherapy called ELI-002 in 25 people with KRAS-mutated pancreatic, colorectal, lung, ovarian, or bile duct cancers that had minimal residual disease after standard treatment. The goal was to see if the treatment is safe and can reduce canc…

This study tested two standard chemotherapy combinations in 150 people with untreated, advanced pancreatic cancer. The goal was to see which treatment works better to control the disease and help patients live longer. Researchers also collected tumor samples to learn more about t…

This study tested a new drug called onvansertib combined with standard chemotherapy for people with advanced pancreatic cancer that had spread. The 41 participants had already tried one type of chemotherapy. The goal was to see if the new combination could shrink tumors or slow t…

This early-phase study tested whether adding a new drug called NP137 to standard chemotherapy (mFOLFIRINOX) is safe for people with locally advanced pancreatic cancer that cannot be removed by surgery. The study involved 43 participants and focused on side effects and how well th…

This study looked at 546 people who had surgery for pancreatic cancer. After surgery, they received chemotherapy with or without an extra drug (erlotinib) and later some also got radiation. The goal was to see if adding these treatments helped people live longer or keep cancer fr…

This study tested a new treatment plan for people with advanced pancreatic cancer that has spread. It combined chemotherapy with drugs that change how genes work and boost the immune system. The goal was to see if the combination is safe and can help control the cancer. 75 patien…

This early-phase study tested a combination of three immunotherapy drugs (nivolumab, BMS-813160, and GVAX) in 22 adults with locally advanced pancreatic cancer that could not be removed by surgery. All participants had already received chemotherapy and radiation. The main goals w…

This study tested a new PET imaging agent (64Cu-DOTA-ECL1i) in 69 people with pancreatic cancer to see if it can detect a specific marker (CCR2) on tumors. The goal was to find out if the scan can predict how well a patient will respond to standard chemotherapy or a targeted ther…

This study tested a new PET imaging agent called [18F]FAPI-74 in 109 people with gastrointestinal cancers, including liver, bile duct, stomach, pancreas, and colorectal cancers. The goal was to see if the scan could accurately find cancer cells by targeting a protein called FAP. …